Imaging of somatostatin-receptor expressing neuroendocrine tumours with 68Ga-DOTATOC-PET/CT versus 111In-DTPA-octreotide SPECT/CT

被引：0
|
作者：
Oeksuez, M. Oe [1 ]
Aschoff, P. [1 ]
Kemke, B. [1 ]
Rauch, D. [1 ]
Zhernosekov, K. [2 ]
Jennwein, M. [2 ]
Roesch, F. [2 ]
Zoller, W. G. [3 ]
Bihl, H. [1 ]
机构：
[1] Katharinen Hosp, Nucl Med & PET Ctr, D-70174 Stuttgart, Germany
[2] Johannes Gutenberg Univ Mainz, D-55122 Mainz, Germany
[3] Katharinen Hosp, D-70174 Stuttgart, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2005年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [21] Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT
    Schreiter, Nils Friedemann
    Bartels, Ann-Mirja
    Froeling, Vera
    Steffen, Ingo
    Pape, Ulrich-Frank
    Beck, Alexander
    Hamm, Bernd
    Brenner, Winfried
    Roettgen, Rainer
    RADIOLOGY AND ONCOLOGY, 2014, 48 (04) : 339 - 347
  • [22] Clinical efficacy of dual-phase scanning using 68Ga-DOTATOC-PET/CT in the detection of neuroendocrine tumours
    Nakamoto, Y.
    Ishimori, T.
    Sano, K.
    Temma, T.
    Ueda, M.
    Saji, H.
    Togashi, K.
    CLINICAL RADIOLOGY, 2016, 71 (10) : 1069.e1 - 1069.e5
  • [23] Impact of Multiphase 68Ga-DOTATOC-PET/CT on Therapy Management in Patients with Neuroendocrine Tumors
    Ruf, Juri
    Heuck, Friederike
    Schiefer, Jan
    Denecke, Timm
    Elgeti, Florian
    Pascher, Andreas
    Pavel, Marianne
    Stelter, Lars
    Kropf, Siegfried
    Wiedenmann, Bertram
    Amthauer, Holger
    NEUROENDOCRINOLOGY, 2010, 91 (01) : 101 - 109
  • [24] Comparison of Ga-68-DOTATATE PET/CT and In-111-octreotide SPECT/CT for the detection of neuroendocrine tumors
    Kieft, M.
    Aalbersberg, E. A.
    Stokkel, M. P. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S91 - S91
  • [25] Comparison of 18F-DOPA PET/CT with 111In-DTPA-octreotide SRS (planar and SPECT/CT imaging) in patients with NET
    Malle, P. B.
    Kohlfuerst, S.
    Igerc, I.
    Lobnig, M.
    Sorschag, M.
    Lind, P.
    Gallowitsch, H. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S439 - S439
  • [26] First-in-human PET/CT Imaging of somatostatin receptor expressing tumors with the novel somatostatin receptor antagonist 68Ga-NODAGA-LM3-a comparison with 68Ga-DOTATOC PET/CT
    Singh, A.
    Kulkarni, H. R.
    Langbein, T.
    Mueller, D.
    Senftleben, S.
    Fani, M.
    Maecke, H.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S184 - S185
  • [27] Comparison of the Effectiveness of 68Ga-DOTATATE PET/CT and 111In-Octreotide SPECT in Patients With Somatostatin Positive Neuroendocrine Tumor
    Kumar, Meena
    Broline, Shelly
    Amerinia, Reza
    Thamake, Sanjay I.
    Ranganathan, David
    Tworowska, Izabela
    Delpassand, Ebrahim S.
    PANCREAS, 2015, 44 (02) : 355 - 355
  • [28] 68Ga-DOTATOC vs. 68Ga-DOTATATE PET/CT in functional imaging of Neuroendocrine Tumours
    Poeppel, T. D.
    Binse, I.
    Petersenn, S.
    Lahner, H.
    Schott, M.
    Antoch, G.
    Brandau, W.
    Bockisch, A.
    Boy, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S97 - S98
  • [29] Gallium-68 somatostatin receptor PET/CT: Is it time to replace 111Indium DTPA octreotide for patients with neuroendocrine tumors?
    Kjell Öberg
    Endocrine, 2012, 42 : 3 - 4
  • [30] Gallium-68 somatostatin receptor PET/CT: Is it time to replace 111Indium DTPA octreotide for patients with neuroendocrine tumors?
    Oberg, Kjell
    ENDOCRINE, 2012, 42 (01) : 3 - 4
12345